SCHEMBL31456004

SCHEMBL31456004

CCCc1cc(OC)c(CC(=O)OCC)cc1OC

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HMGCR P04035 2/20 0.49
CYP3A4 P08684 1/20 0.49
DPP4 P27487 2/20 0.48
TAAR1 Q96RJ0 2/20 0.45
ALDH1A1 P00352 3/20 0.44
KMT2A Q03164 3/20 0.44
KDM4E B2RXH2 2/20 0.44
MEN1 O00255 2/20 0.44
GAA P10253 2/20 0.40
GLA P06280 1/20 0.40
MAPT P10636 1/20 0.40
HPGD P15428 1/20 0.40
RUNX1 Q01196 1/20 0.40
CBFB Q13951 1/20 0.40
CA1 P00915 2/20 0.40
CA2 P00918 2/20 0.40
CA9 Q16790 2/20 0.40
NR4A1 P22736 1/20 0.40
HCAR2 Q8TDS4 1/20 0.40
CA12 O43570 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31455983 0.83 CA1 (0.51) CYP3A4DPP4TAAR1ALDH1A1CA1
SCHEMBL17722574 0.81 CYP4F2 (0.54) CYP3A4DPP4TAAR1ALDH1A1KMT2A
SCHEMBL31116543 0.81 DPP4 (0.48) CYP3A4DPP4ALDH1A1KMT2AKDM4E
SCHEMBL2064203 0.81 DPP4 (0.48) DPP4ALDH1A1KMT2AKDM4EMEN1
SCHEMBL31395505 0.79 EGFR (0.51) DPP4ALDH1A1KMT2AKDM4EMEN1
SCHEMBL21455751 0.79 ALDH1A1 (0.53) DPP4ALDH1A1KMT2AKDM4EMEN1
SCHEMBL30482840 0.79 ALDH1A1 (0.53) DPP4ALDH1A1KMT2AKDM4EMEN1
SCHEMBL5309200 0.79 TAAR1 (0.65) TAAR1
SCHEMBL14570472 0.79 TAAR1 (0.65) TAAR1
SCHEMBL8282635 0.79 CYP3A4 (0.51) CYP3A4DPP4TAAR1ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025059373-A1 NOVEL PHENALKYLAMINES AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS GILGAMESH PHARMACEUTICALS, INC. (US) 2025-03-20 WO disclosed